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Background and Purpose: Hydrogen (H2) has been shown to have a strong
antioxidant effect on preventing oxidative stress-related diseases. The goal of the
present study is to determine the pharmacodynamics of H2 in a model of isoproterenol
(ISO)-induced cardiac hypertrophy.
Methods: Mice (C57BL/6J; 8–10 weeks of age) were randomly assigned to four
groups: Control group (n = 10), ISO group (n = 12), ISO plus H2 group (n = 12),
and H2 group (n = 12). Mice received H2 (1 ml/100g/day, intraperitoneal injection)
for 7 days before ISO (0.5 mg/100g/day, subcutaneous injection) infusion, and then
received ISO with or without H2 for another 7 days. Then, cardiac function was evaluated
by echocardiography. Cardiac hypertrophy was reflected by heart weight/body weight,
gross morphology of hearts, and heart sections stained with hematoxylin and eosin,
and relative atrial natriuretic peptide (ANP) and B-type natriuretic peptide (BNP) mRNA
levels. Cardiac reactive oxygen species (ROS), 3-nitrotyrosine and p67 (phox) levels were
analyzed by dihydroethidium staining, immunohistochemistry and Western blotting,
respectively. For in vitro study, H9c2 cardiomyocytes were pretreated with H2-rich
medium for 30 min, and then treated with ISO (10 µM) for the indicated time. The
medium and ISO were re-changed every 24 h. Cardiomyocyte surface areas, relative
ANP and BNP mRNA levels, the expression of 3-nitrotyrosine, and the dissipation of
mitochondrial membrane potential (MMP) were examined. Moreover, the expression of
extracellular signal-regulated kinase1/2 (ERK1/2), p-ERK1/2, p38, p-p38, c-Jun NH2-
terminal kinase (JNK), and p-JNK were measured by Western blotting both in vivo and
in vitro.
Results: Intraperitoneal injection of H2 prevented cardiac hypertrophy and improved
cardiac function in ISO-infused mice. H2-rich medium blocked ISO-mediated
cardiomyocytes hypertrophy in vitro. H2 blocked the excessive expression of NADPH
oxidase and the accumulation of ROS, attenuated the decrease of MMP, and inhibited
ROS-sensitive ERK1/2, p38, and JNK signaling pathways.
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Conclusion: H2 inhibits ISO-induced cardiac/cardiomyocytes hypertrophy both in vivo
and in vitro, and improves the impaired left ventricular function. H2 exerts its protective
effects partially through blocking ROS-sensitive ERK1/2, p38, and JNK signaling
pathways.
Keywords: hydrogen, β-adrenoceptor, cardiac hypertrophy, NADPH oxidase, reactive oxygen species,
mitochondrial damage, MAPK
INTRODUCTION
Heart failure is a global pandemic affecting an estimated 26
million people worldwide, posing an enormous burden to both
individuals and society (Ambrosy et al., 2014). Heart failure
is often preceded by left ventricular hypertrophy, which is
characterized by an increase in the size of individual cardiac
myocytes and re-expression of fetal cardiac genes, such as atrial
natriuretic peptide (ANP) and B-type natriuretic peptide (BNP;
Magga et al., 1998; Heineke and Molkentin, 2006). Although
cardiac hypertrophy has traditionally been considered as an
adaptive response required to sustain cardiac output in response
to stresses, long-standing hypertrophy will eventually lead to
congestive heart failure, arrhythmia, and sudden death (Frey and
Olson, 2003).
Increasing evidence suggests that diverse pathophysiological
stimuli, including neurohumoral activation [such as
angiotensin II (ANG II) and β-adrenoceptor stimulation],
hypertension, ischemic heart diseases, myocarditis, and diabetic
cardiomyopathy, will contribute to cardiac hypertrophy and
heart failure partially via inducing the production of excessive
reactive oxygen species (ROS; Li et al., 2002; Zhang et al., 2007b;
Zhang et al., 2015). The nicotinamide adenine dinucleotide
phosphate (NADPH) oxidase and mitochondria have been
proposed as primary sites of ROS generation (Dai et al.,
2011a). ROS generated by NADPH oxidase was shown to
stimulate and amplify mitochondrial ROS production and
induce mitochondrial dysfunction, which can be reflected by the
depression of mitochondrial membrane potential (MMP; Zorov
et al., 2000; Dai et al., 2011a). The excessive accumulation of
ROS subsequently activates downstream ROS-sensitive signaling
pathways implicated in pathological cardiac hypertrophy.
Therefore, blocking ROS will improve mitochondrial function
and block downstream hypertrophic signaling, thus preventing
the development of cardiac hypertrophy and progression to
heart failure. Consistent with this notion, recent studies revealed
that strategies targeted ROS and downstream signaling pathways
modulated by ROS could be a better approach to improve cardiac
hypertrophy (Burgoyne et al., 2012).
Molecule hydrogen (H2), which is a colorless, odorless,
tasteless, and flammable gas, has attracted considerable attention
for improving oxidative stress-related diseases (Ohta, 2015). We
recently revealed that intraperitoneal injection of H2 protects
against vascular hypertrophy induced by abdominal aortic
coarctation (AAC) in vivo, and H2-rich medium attenuates
proliferation and migration of vascular smooth muscle cells
(VSMCs) stimulated by ANG II in vitro (Zhang et al., 2016).
Moreover, H2 also has important role in protecting against heart
diseases. Inhalation of H2 attenuates left ventricular remodeling
induced by intermittent hypoxia (Hayashi et al., 2011; Kato et al.,
2014), and improves cardiac hypertrophy after germinal matrix
hemorrhage in neonatal rats (Lekic et al., 2011). However, the
effects of H2 on cardiac hypertrophy induced by β-adrenoceptor
stimulation and the related signaling mechanisms still remain
unclear. The aims of this study are, therefore, to determine
the effect of intraperitoneal injection of H2 on isoproterenol
(ISO)-induced cardiac hypertrophy in vivo, and the effect of H2-
rich medium on ISO-induced H9c2 cardiomyocytes hypertrophy
in vitro, as well as to identify the molecular mechanisms that may
be responsible for its putative effects.
MATERIALS AND METHODS
Drugs and Chemicals
H2 (99.999%; Guang Zhou Guang Qi GAS Co., Ltd, Guangdong,
China) was stored in the seamless steel gas cylinder, and it
was injected into an aseptic soft plastic infusion bag (100 ml;
CR Double-Crane Pharmaceuticals Co., Ltd, Anhui, China)
under sterile conditions immediately before intraperitoneal
injection. ISO (I5627, Sigma–Aldrich, St. Louis, MO, USA) was
dissolved in normal saline (5 mg/10 ml) under sterile conditions
immediately before subcutaneous injection, and dissolved in
double distilled water as 10 mM stock solution 30 min before
use. The antibodies against extracellular signal-regulated kinase
1/2 (ERK1/2), p-ERK1/2, p38, p-p38, c-Jun NH2-terminal
kinase (JNK), and p-JNK, p67 (phox) were from Cell Signaling
Technology (Danvers, MA, USA). The antibody against β-actin
was from Santa Cruz Biotechnology (Santa Cruz, CA, USA).
Anti-α-actin antibody was from Sigma–Aldrich (St. Louis, MO,
USA). The antibody against 3-nitrotyrosine was from Abcam
(Cambridge, MA, USA). JC-1 was from Beyotime Biotechnology
(C2006, Jiangsu, China).
Preparation of H2-rich Medium and
Measurement of H2 Concentration
H2-rich medium was prepared as previously described (Zhang
et al., 2016). The concentration of H2 was measured by
MB-Pt reagent (generously provided by Ming Yan, Shanghai
Nanobubble Technology Co., Ltd, Shanghai, China) as previously
described (Zhang et al., 2016). The H2 concentration in our
H2-rich medium was no less than 0.6 ppm (0.6–0.9 ppm).
Cell Culture and Treatment
H9c2 rat cardiac myoblasts (a cardiomyoblast cell line derived
from embryonic rat heart tissue; generously provided by Prof.
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Hongliang Li, Wuhan University, China) were grown in DMEM
containing 5.5 mM glucose as described previously (Jeong et al.,
2009). To induce hypertrophy, cells were serum starved for 18 h
in DMEM containing 1% FBS, and then treated with 10 µM ISO
for 48 h (Jeong et al., 2009). In order to investigate the effect of H2
on the blockage of ISO-induced hypertrophy, H2-rich medium
was added 30 min before ISO administration, the medium,
and ISO were re-changed every 24 h, and cardiomyocytes
hypertrophic response was examined after 48 h of ISO challenge
(Jeong et al., 2009).
Animal Model of Cardiac Hypertrophy
and Treatment Protocol
The C57BL/6J mice (aged 8–10 weeks, male) were obtained from
the Laboratory Animal Center of Sun Yat-sen University. The
animals were housed with 12-h light–dark cycles and allowed to
obtain food and water ad libitum. All experimental procedures
and protocols were approved by Institutional Animal Care and
Use Committee (Zhongshan School of Medicine, Sun Yat-sen
University), and conformed to the Guide for the Care and Use
of Laboratory Animals published by the National Institutes of
Health (NIH publication NO. 85-23, revised 1996).
Cardiac hypertrophy was induced by subcutaneous injection
of ISO (0.5 mg/100g/day) for 7 days as previously revealed
(Tshori et al., 2006). Mice were randomly assigned to four groups:
Control (Con) group (n = 10), ISO group (n = 12), ISO plus
H2 group (n = 12), and H2 group (n = 12). H2 was given at the
dose of 1 ml/100g/day by intraperitoneal injection as previously
described (Huang et al., 2013; Zhang et al., 2016). Mice in ISO
plus H2 group and H2 group received H2 consecutively for 7 days
before receiving ISO, and continued for another 7 days. On the
8th day, mice in ISO group, and ISO plus H2 group received
ISO for 7 days until animals were sacrificed on the 15th day.
After sacrifice, hearts were excised, rinsed with ice-PBS, and
blotted dry. Hearts were weighed; the heart weight/body weight
(HW/BW) ratios were calculated and expressed as milligrams
HW per gram BW. Then hearts were snap frozen in liquid
nitrogen within minutes and stored at−80◦C until analyzed.
Echocardiography
Transthoracic echocardiography was performed to assess left
ventricular function before sacrificed on the 15th day in a blinded
manner. Mice were anesthetized with 1.5–2% isoflurane, and
hearts were visualized using a RMV707B (30 M Hz) scan-head
interfaced with a Vevo-2100 high frequency ultrasound system
(VisualSonics Inc., Toronto, Canada) at least three times for each
animal indicated (Webb et al., 2010).
Histological Analysis
Hearts were excised, washed with ice-PBS, fixed in 10% buffered
formalin, and cut transversely close to the apex cordis to visualize
the left and right ventricles. Several sections of heart (4–5 µm
thickness) were prepared and stained with hematoxylin and
eosin (H&E) for histopathology and then visualized by light
microscopy.
Immunohistochemistry
For immunostaining, anti-sarcomeric α-actin antibody was used
to assess the cell surface area of H9c2 cardiomyocytes as described
previously (Akimoto et al., 1996). To assess 3-nitrotyrosine
levels in heart, which can reflect formation of ONOO–, primary
antibody against 3-nitrotyrosine (1:50) was used as previously
described (Zhang et al., 2011).
Measurement of MMP
Mitochondrial membrane potential was determined by the
dye 5,5′,6,6′-tetrachloro-1,1′,3,3′-tetraethylbenzimidazolcarbo-
cyanine iodide (JC-1) as previously described with slight
modification (Cossarizza et al., 1993). Briefly, the treated cells
were washed with PBS, and then incubated with JC-1 staining
dye (culture medium: JC-1 working dye = 1:1) at 37◦C in the
dark for 20 min and rinsed three times with cold PBS, and
analyzed by fluorescence microscope (Axio Observer Z1, Carl
Zeiss. Inc.). The JC-1 aggregates, which was accumulated in
the inner membrane of mitochondria, emitted red fluorescence
and represented the high MMP, while green fluorescence
reflected JC-1 monomer which entered in the cytosol following
mitochondrial membrane depolarization. When mitochondria
is damaged, the red/green ratio decreases. The ratio of JC-1
aggregates to monomer (red/green) intensity for each region was
calculated by Image-Pro Plus software (version 6.0).
qRT-PCR
Total mRNA was extracted from left ventricles and H9c2
cardiomyocytes using TRIZol reagent (15596-026, Invitrogen)
according to the manufacturer’s instruction, and cDNA was
synthesized using oligo (dT) primers with the Transcriptor First
Strand cDNA Synthesis Kit (PrimeScriptTM RT Master Mix,
Takara). Selected gene differences were confirmed by qRT-PCR
using SYBR green (SYBR R© Premix Ex TaqTM, Takara). The target
gene expression was normalized to GAPDH gene expression. The
primers for qRT-PCR are shown in Table 1.
Western Blotting
Western blotting was performed as previously described
(Zhang et al., 2016). The membranes were incubated with
primary (1:2000) and secondary (1:2000) antibodies by standard
techniques. Immunodetection was accomplished using enhanced
chemiluminescence (ChemiDoc XRS+ System, Bio-Rad,
Hercules, CA, USA).
TABLE 1 | The primers for qRT-PCR.
Name Forward primer sequence
(5′–3′)
Reverse primer sequence
(5′–3′)
M-GAPDH GGTTGTCTCCTGCGACTTCA TGGTCCAGGGTTTCTTACTCC
R-GAPDH GACATGCCGCCTGGAGAAAC AGCCCAGGATGCCCTTTAGT
M-ANP GTCTTGCCTCTCCCACTCTG TTCGTCCTTGGTGCTGAAGT
R-ANP GGGAAGTCAACCCGTCTCA GGCTCCAATCCTGTCAATCC
M-BNP TCTGGGACCACCTTTGAAGT ATGTTGTGGCAAGTTTGTGC
R-BNP CTCCAGAACAATCCACGATG ACAGCCCAAGCGACTGACT
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FIGURE 1 | Effects of hydrogen (H2) on cardiac hypertrophy induced by isoproterenol (ISO) in vivo. (A) Gross morphology of hearts (top) and heart sections
stained with H&E (bottom) after 1 week of ISO infusion with or without H2 at the dose of 1 ml/100g/day. (B) The relative mRNA expression of hypertrophic marker
atrial natriuretic peptide (ANP) to GAPDH (n = 3). (C) The relative mRNA expression of hypertrophic marker B-type natriuretic peptide (BNP) to GAPDH (n = 3).
∗P < 0.05 vs. Control (Con) and #P < 0.05 vs. ISO. Scale bar: 20 µm.
Assessment of Cardiac ROS Levels
Cardiac total ROS was stained with dihydroethidium (DHE,
D-23107; Invitrogen) on fresh frozen sections as previously
described (Zhang et al., 2014). Images were immediately acquired
using confocal microscopy (Leica Model SPE, Leica Imaging
Systems Ltd) using λex 405 nm laser excitation.
Statistical Analysis
Data are expressed as mean ± SD. Differences among groups
were tested by one-way ANOVA. Comparisons between two
groups were performed by unpaired Student’s t-test. A value of
P < 0.05 was considered to be significantly different.
RESULTS
H2 inhibited Cardiac Hypertrophy In vivo
In order to investigate the effects of H2 on cardiac hypertrophy,
ISO was used to induce cardiac hypertrophy in mice. As
expected, mice with chronic ISO infusion exhibited cardiac
hypertrophy compared to the control group, as indicated by
the gross morphology of hearts, heart sections stained with
H&E (Figure 1A). The hypertrophic marker gene ANP and
BNP mRNA levels (Figures 1B,C, P < 0.05 vs. Con), and
HW/BW ratio (Table 2, P < 0.05 vs. Con) were also increased.
Pretreatment with H2 (intraperitoneal injection) at the dose of
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TABLE 2 | Effects of hydrogen on cardiac dysfunction induced by isoproterenol (ISO) in vivo.
Parameter Con ISO ISO+H2 H2
Number (n) 10 12 12 12
HW/BW (mg/g) 4.72 ± 0.08 5.81 ± 0.07∗ 5.09 ± 0.14# 4.69 ± 0.06
LVEDD (mm) 3.24 ± 0.10 3.71 ± 0.06∗ 3.45 ± 0.01# 3.26 ± 0.08
LVESD (mm) 2.05 ± 0.05 2.52 ± 0.07∗ 2.35 ± 0.04# 2.12 ± 0.07
FS (%) 35.99 ± 0.13 31.56 ± 0.19∗ 33.30 ± 0.45# 35.68 ± 0.26
Hydrogen was given at the dose of 1 ml/100g/day by intraperitoneal injection. Heart weight, HW; Body weight, BW; LVEDD, left ventricular end-diastolic diameter; LVESD,
left ventricular end-systolic diameter. ∗P < 0.05 vs. Con and #P < 0.05 vs. ISO.
FIGURE 2 | Effects of H2-rich medium on cardiomyocytes hypertrophy induced by ISO in vitro. (A) Photomicrographs of morphological change induced by
ISO with or without H2-rich medium. (B) Bar graph shows the relative cell surface area of cardiomyocytes stimulated by ISO with or without H2-rich medium. (C) The
relative mRNA levels of hypertrophic marker ANP to GAPDH (n = 4). (D) The relative mRNA levels of hypertrophic marker BNP to GAPDH (n = 4). ∗P < 0.05 vs. Con
and #P< 0.05 vs. ISO. Scale bar: 20 µm.
1 ml/100g/day reversed these hypertrophic responses (Figure 1;
Table 2, P < 0.05 vs. ISO). Moreover, H2 injection alleviated the
impaired left ventricular function, as evidenced by decreasing left
ventricular end-systolic diameter (LVESD), left ventricular end-
diastolic diameter (LVEDD), and increasing fractional shortening
(FS%; Table 2, P < 0.05 vs. ISO). However, there were no
significant changes between control group and H2 group.
Collectively, these data suggested that H2 injection prevented the
development of ISO-induced cardiac hypertrophy and preserved
cardiac function in vivo.
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FIGURE 3 | Effects of H2 on the generation of Reactive oxygen species (ROS) induced by ISO both in vivo and in vitro. (A) Total ROS was stained with
dihydroethidium (DHE) in the heart infused by ISO 1 week with or without H2 at the dose of 1 ml/100g/day. (B) Cardiac 3-nitrotyrosine (3-NT) was stained by
immunohistochemistry in different groups. (C) Representative Western blotting and quantification of 3-NT to β-actin in H9c2 cardiomyocytes stimulated by ISO for
5 min with or without H2-rich medium for 30 min pretreatment (n = 4). (D) Representative Western blotting and quantification of p67 (phox) to β-actin in the hearts
(n = 4). ∗P < 0.05 vs. Con and #P < 0.05 vs. ISO. Scale bar: 5 µm.
H2 attenuated Cardiomyocyte
Hypertrophy In vitro
As the heart primarily consists of cardiomyocyte and
fibroblast, therefore, we investigated whether H2 could
target cardiomyocyte for hypertrophic inhibition. H2-rich
medium and H9c2 cardiomyocytes were used for in vitro
studies. First, we used CCK8 to investigate the possible
cytotoxity of H2-rich medium on H9c2 cardiomyocyte. H2
was shown to be non-cytotoxic for cardiomyocyte treating
with H2-rich medium for 48 h (data not shown). After
48 h of ISO stimulation, cardiomyocyte surface areas,
and the hypertrophic marker gene ANP and BNP mRNA
levels were significantly increased in H9c2 cardiomyocyte
(Figures 2A–D, P < 0.05 vs. Con). H2-rich medium
attenuated these hypertrophic responses of H9c2 cardiomyocyte
(Figures 2A–D, P < 0.05 vs. ISO). These data indicated that
H2 could also inhibit ISO-induced cardiomyocyte hypertrophy
in vitro.
H2 Blocked the Excess ROS
Accumulation and Mitochondrial
Damage
ROS play a critical role in the development of cardiac
hypertrophy and heart failure (Burgoyne et al., 2012). ROS
levels were increased in the left ventricular of ISO-infused
mice compared with control mice, and this increase was
inhibited by pretreatment with H2 at the dose of 1ml/100g/day
(Figure 3A). Moreover, another oxidative stress marker, 3-
nitrotyrosine (3-NT), which reflects the formation of ONOO–,
was also upregulated by ISO stimuli, and suppressed by H2
(Figure 3B). To confirm these in vivo findings, we evaluated
the effects of H2-rich medium on the levels of 3-NT stimulated
by ISO in vitro. The accumulation of 3-NT was increased after
ISO stimulation, while H2-rich medium attenuated this effects
(Figure 3C, P < 0.05).
To further understand the mechanism of H2 in blocking
ROS accumulation, we tested the NADPH oxidase subunit p67
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FIGURE 4 | Effects of H2-rich medium on ISO-induced depression of MMP in vitro. After stimulated by ISO for 24 h with or without H2-rich medium for
30 min pretreatment, MMP was measured by JC-1 staining followed by photofluorography (A). The quantification of the fluorescence intensity (red/green ratio) for
each treatment was calculated by Image-Pro Plus software (B) (n = 4). ∗P < 0.05 vs. Con and #P < 0.05 vs. ISO. Scale bar: 5 µm.
(phox) expression. Immunoblotting revealed the expression of
p67 (phox) was increased in left ventricular of ISO-infused mice,
and this increase was alleviated by H2 (Figure 3D, P < 0.05).
As we have mentioned above, NADPH oxidase-derived ROS can
stimulate and amplify mitochondrial ROS production and induce
mitochondrial dysfunction (Zorov et al., 2000; Dai et al., 2011a),
and these can be reflected by the change of MMP. ISO induced
the depression of MMP, as indicated by high levels of green
fluorescence and low levels of red fluorescence. Interestingly,
H2-rich medium blocked the depression of MMP induced by
ISO (Figures 4A,B, P < 0.05). Therefore, these data indicated
that H2 inhibited the excess ROS accumulation following ISO
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FIGURE 5 | The time-dependent effects of ISO on MAPKs activation in vitro. Representative Western blot and quantification of ERK1/2 phosphorylation (A),
or p38 phosphorylation (B), or JNK phosphorylation (C) to their total protein expressions, respectively, n = 4. ∗P < 0.05 vs. 0 min.
stimuli through attenuating NADPH oxidase expression and
mitochondrial damage.
H2 suppressed Mitogen-Activated
Protein Kinases (MAPKs) Signaling In
vivo and In vitro
Based on the inhibitory effect of H2 on the ISO-induced
excess accumulation of ROS in vitro and in vivo, we further
investigated its effect on the downstream hypertrophic targets,
such as mitogen-activated protein kinases (MAPKs) signaling
pathways. Following ISO stimuli, the phosphorylation of ERK1/2,
p38 MAPK (p38), and c-Jun NH2-terminal kinase (JNK) were
increased to the high level at 5 min, and came to the base line at
30 min (Figure 5, P< 0.05 vs. 0 min). These enhanced activation
of MAPKs could be blocked by H2-rich medium in vitro
(Figure 6; P < 0.05 vs. ISO). Similarly, the activation of MAPKs
were enhanced in the hearts of ISO-infused mice compared with
control group (Figure 7, P < 0.05 vs. Con). Such changes were
inhibited by pretreatment with H2 in vivo (Figure 7, P < 0.05
vs. ISO). Thus, H2 suppressed the enhanced phosphorylation
of ERK1/2, p38, and JNK to alleviate ISO-mediated cardiac
hypertrophy in vivo and cardiomyocyte hypertrophy in vitro.
DISCUSSION
The present study demonstrates that intraperitoneal injection
of H2 protects against ISO-induced cardiac hypertrophy
and dysfunction in vivo and H2-rich medium attenuates
ISO-mediated cardiomyocyte hypertrophy in vitro. The
cardioprotection of H2 is mediated by direct interruption of
NADPH oxidase expression and alleviating mitochondrial
damage, these lead to inhibit the accumulation of ROS,
and subsequently block downstream ERK1/2, p38, and JNK
signaling.
H2 has been emerged as an important blocker of heart
diseases by various given manners. H2 inhalation attenuates
intermittent hypoxia (Hayashi et al., 2011; Kato et al., 2014), or
ischemia/reperfusion (Hayashida et al., 2008), or germinal matrix
hemorrhage-induced left ventricular remodeling (Lekic et al.,
2011). Drinking H2-rich water blocks cardiac fibrosis induced
by left kidney artery ischemia/reperfusion injury (Zhu et al.,
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FIGURE 6 | Effects of H2-rich medium on ISO-mediated MAPKs signaling activation in vitro. Representative Western blot and quantification of ERK1/2
phosphorylation (A), p38 phosphorylation (B), and JNK phosphorylation (C) to their total protein expressions, respectively, n = 4. ∗P < 0.05 vs. Con and #P < 0.05
vs. ISO.
2011). H2-rich saline injection also inhibits ischemia/reperfusion
(Sun et al., 2009), or hypertension-mediated cardiac remodeling
(Wang et al., 2011; Yu and Zheng, 2012). However, the effects of
intraperitoneal injection of H2 on cardiac hypertrophy induced
by β-adrenoceptor stimulation have not yet been clarified. In
this study, we prepared H2-rich medium, and developed new
methods for giving H2 in vivo by intraperitoneal injection of
H2, and we find that H2 not only attenuates ISO-induced
cardiomyocyte hypertrophy in vitro and cardiac hypertrophy
in vivo, but also improves the impaired cardiac function. As
we have mentioned above, diabetic cardiomyopathy is also
a contributor to cardiac hypertrophy and heart failure. H2-
rich saline has been reported to improve early neurovascular
dysfunction (Feng et al., 2013) and erectile dysfunction
(Fan et al., 2013) in a streptozotocin-induced diabetic rat
model. However, the effect of H2 on diabetic cardiomyopathy
is still under investigation. It has been reported that the
gasotransmitter hydrogen sulfide (H2S) protects against pressure
overload-mediated (Kondo et al., 2013) or arteriovenous fistula
(AVF)-induced heart failure (Mishra et al., 2010). A question
raised here is that whether the reciprocal interaction between H2
and H2S exists during their regulation of cardiac hypertrophy.
The excess activation of ROS has been shown to contribute to
the development of cardiac hypertrophy (Li et al., 2002; Zhang
et al., 2005, 2007b; Burgoyne et al., 2012). In this study, we reveal
that H2 blocks ROS accumulation induced by β-adrenoceptor
stimulation both in vitro and in vivo. The inhibitory effects of
H2 on ROS also have been reported in various animal models,
such as heart ischemia/reperfusion injury (Zhang et al., 2011;
Noda et al., 2013; Shinbo et al., 2013), brain injury (Ohsawa et al.,
2007; Liu et al., 2011; Wang et al., 2012), renal injury (Li et al.,
2016), chemotherapy-induced ovarian injury (Meng et al., 2015),
metabolic syndrome (Song et al., 2013), etc. NADPH oxidase
and mitochondria have been proposed as primary sites of ROS
generation (Dai et al., 2011a). ROS produced by NADPH oxidase
has the ability to stimulate and amplify mitochondrial ROS
generation and induce mitochondrial dysfunction (Zorov et al.,
2000; Dai et al., 2011a). Therefore, tyrosine kinase FYN interacts
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FIGURE 7 | Effects of H2 (1 ml/100g/day) on MAPKs signaling activation induced by ISO in vivo. Representative Western blotting and quantification of
ERK1/2 phosphorylation (A), or p38 phosphorylation (B), or JNK phosphorylation (C) to their total protein expressions, respectively, n = 4. ∗P < 0.05 vs. Con and
#P < 0.05 vs. ISO.
with the C-terminal domain of NOX4, and phosphorylates
the tyrosine 566 on NOX4, thereby inhibiting apoptosis in
the heart and preventing cardiac remodeling after pressure
overload (Matsushima et al., 2016). Overexpression of catalase
targeted to mitochondria, but not the overexpression of wild-type
peroxisomal catalase, protects against ANG II-induced cardiac
hypertrophy, fibrosis and mitochondrial damage, as well as heart
failure induced by overexpression of Gαq (Dai et al., 2011b). We
found that H2 inhibits ISO-induced NADPH oxidase subunit p67
expression, and suppresses the dissipation of MMP.
The excessive accumulation of ROS subsequently transmits
signals to downstream ROS-sensitive signaling pathways, such
as ERK1/2 (Li et al., 2002; Dai et al., 2011b), p38 MAPK
(Li et al., 2002; Dai et al., 2011a), and JNK (Li et al., 2002;
Kimura et al., 2005; Zhang et al., 2007a), NF-κB (Hirotani
et al., 2002), PI3K/Akt (Sundaresan et al., 2009; Wang et al.,
2013), and autophagy related signaling (Dai et al., 2011b), to
induce pathological cardiac hypertrophy. Our results indicate
that H2 markedly blocks ISO-induced ERK1/2, p38 and JNK
activation in vivo and in vitro. These findings confirm that
the anti-hypertrophic effect of H2 is partially achieved through
blocking ROS-dependent MAPKs signaling. Yu Yongsheng et al.
has reported that H2-rich saline inhibits cardiac hypertrophy
in spontaneous hypertensive rats (SHRs) via blocking NF-
κB activity (Yu and Zheng, 2012). H2-rich saline reduces
myocardial reperfusion injury and improves heart function
through down-regulating the expression of Akt and GSK3β
(Yue et al., 2015), and blocking autophagy in myocardial
tissue (Pan et al., 2015). However, whether PI3K/Akt, and
autophagy signaling are related to the protective effects of H2
injection on pathological cardiac hypertrophy still needs further
investigation.
CONCLUSION
Our study demonstrated that intraperitoneal injection of
H2 attenuated β-adrenoceptor agonist (ISO)-mediated cardiac
hypertrophy and dysfunction in vivo, and H2-rich medium
blocked ISO-induced cardiomyocyte hypertrophic responses
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in vitro. Our results suggested that H2 exerted anti-hypertrophic
activity, at least in part, via alleviating NADPH oxidase
expression and inhibiting the depression of MMP, and thus
blocked ROS-sensitive MAPK signaling pathways.
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